

Re: FDA approves Pfizer nerve pain drug ~ Lyrica

Source: <http://sci.tech-archive.net/Archive/sci.med.cardiology/2005-01/0178.html>

From: Sharon Hope (*shope_at_anet.net*)

Date: 01/05/05

Date: Wed, 05 Jan 2005 03:05:19 GMT

Don confused her teaching at USC and UCSD and her NIH statin study with her practice.

Her practice is at the VA.

As for the rest of her CV, I think her accomplishments are worthy of admiration and deserve notice.

"listener" <listener@nospam.net> wrote in message

news:Xns95D4622098E03some1outthere@38.144.126.109...

> *Where is Don questioning Dr. Golomb's credentials? I missed that. And*

> *ehat do *her* credentials have to do with *your* statements?*

>

> *This semms like just another non-response response, which you and zee are*

> *very good at. It's just like a shell game: throw out erroneous or bogus*

> *"facts" (which, of course, you're free to do) and when questioned on*

> *them, divert attention.*

>

>

> *L*

>

>

> *"Sharon Hope" <shope@anet.net> wrote in*

> *news:qinCd.745407\$mD.158002@attbi_s02:*

>

>> *You are ignorant of the facts in this case.*

>>

>> *Dr. Golomb does not practice at the university. Her practice is at*

>> *the VA Medical Center.*

>>

>> *A renaissance woman, she is the NIH Principal Investigator for the NIH*

>> *Statin Study (which accepts no drug company funding), and concurrently*

>> *she is teaching at two universities, and a RAND researcher. She is*

>> *also the US DOD's expert on Gulf War Syndrome.*

>>

>> *Her credentials are readily accessible (CV below). What are your*

>> *credentials?*

>>

>> *Her CV:*

>> <http://medicine.ucsd.edu/faculty/golomb/>

>>

>> *CURRICULUM VITAE*

>> *Beatrice Alexandra Golomb, MD, PhD*

>> *CURRENT POSITIONS*

>>

>> *a.. Assistant Professor of Medicine, U.C. San Diego April 1998–*

>> *Division of General Internal Medicine*

>>

>>

>> *b.. Staff Physician, San Diego VA Medical Center Aug 1, 1996 –*

>> *Division of General Internal Medicine*

>> *3350 La Jolla Village Dr.*

>> *San Diego, CA 92161*

>>

>>

>> *c.. Research Associate Professor, Dept. of Psychology, USC: Oct*

>> *1998– Social Science Research Institute*

>> *University of Southern California*

>> *University Park Los Angeles, CA 90089–0375*

>>

>>

>> *d.. Health Consultant, RAND: Aug 1996 –*

>> *1700 Main St.,*

>> *M–28 P.O. Box 2138*

>> *Santa Monica, CA 90408–2138*

>> *(310) 393–0411 x6606*

>> *EDUCATION AND TRAINING*

>>

>> *EDUCATION*

>>

>> *a.. BS, Physics, Summa Cum Laude, University of Southern California,*

>> *1979*

>>

>>

>> *b.. Medical Scientist Training Program, University of California,*

>> *San*

>> *Diego, June, 1979*

>>

>>

>> *c.. PhD, Biology, University of California, San Diego, June, 1988*

>>

>>

>> *d.. MD, University of California, San Diego, June, 1989*

>>

>>

>> *e.. Postdoctoral Fellow, Computational Neurobiology Laboratory, Salk*

>> *Institute, 1989–1990*

>>

>>

>> *f.. Medical Resident, West Los Angeles V. A. Medical Center,*
>> 1990–1993

>>

>>

>> *g.. Chief Medical Resident, West Los Angeles V. A. Medical Center,*
>> 1993–1994

>>

>>

>> *h.. Robert Wood Johnson Clinical Scholar, UCLA, 1994–1996*

>> MAJOR AREAS OF TRAINING

>>

>> *a.. Physics (BS)*

>> *b.. Neurobiology (PhD)*

>> *c.. Neural Networks (Postdoctoral fellowship)*

>> *d.. Internal Medicine (MD, internship, residency, chief residency)*

>> *e.. Health Services Research & Research methodology (Robert Wood*

>> *Johnson*

>> *Clinical Scholarship)*

>> *Back to Top*

>>

>>

>> -----

>>

>> *LICENSURE: California, Issued 10–8–91*

>>

>> BOARD CERTIFICATION

>>

>> *Diplomate, American Board of Internal Medicine, September 1993*

>>

>> *Diplomate, American Board of Forensic Examiners*

>>

>> *Back to Top*

>>

>>

>>

>>

>> -----

>>

>> PROFESSIONAL ACTIVITIES AND AFFILIATIONS

>>

>> *Member, Medical Science Training Program Student Advisory Committee,*

>> *UCSD School of Medicine, September, 1999–*

>>

>> *Associate Fellow, American Heart Association Council on Epidemiology*

>> *and Prevention, elected March 25, 1999*

>>

>> *Fellow, 23rd Annual 10–day Seminar on the Epidemiology and Prevention*

>> *of Cardiovascular Diseases, 1997*

>>

>> *Diplomate and member, American College of Forensic Examiners, 1996–*
>>
>> *Member, American College of Physicians, March 1995–*
>>
>> *Pharmacy and Therapeutics Committee, WLA VA Medical Center, 1993–1994*
>>
>> *Ethics Committee, West LA VA Medical Center, 1991–1994*
>>
>>
>> *Peer Reviewer in various journals including: JAMA, BMJ, Circulation, J*
>> *Clin Epi, Am J Med, Ann Behav Med, Psychosomatic Med, Psychiatric*
>> *Services, Am J Epi, Am J Primatology, Complex Systems, Evolutionary*
>> *Anthropology, J Gen Internal Med, & Medical Care*
>>
>> *Peer Review participation, Books: Oxford University Press*
>>
>>
>> *Back to Top*
>>
>>
>>

>> -----
>>
>> *AWARDS AND HONORS*
>>
>> *a.. Who's Who in America, 2000*
>> *b.. Solomon Scholar Research Award, UCLA, 1993*
>> *c.. Solomon Scholar Research Award 1992*
>> *d.. Phi Kappa Phi, 1979*
>> *e.. Emma Josephine Bradley Bovard Award, 1979*
>> *f.. Junior Phi Beta Kappa, 1978*
>>
>> *Back to Top*
>>
>>
>>

>> -----
>>
>> *RESEARCH GRANTS AND TOPICS OF INTEREST*
>>
>> *RESEARCH GRANTS*
>>
>> *Funded: NIH ROI*
>>
>>
>> *Project Title: Statins and Noncardiovascular Endpoints*
>>
>> *Project Number; 98–1060*
>>

>> *Amount (Total direct costs over 5 years) \$4.1 million*

>>

>> *Dates: 8–1999 to 7–2004*

>>

>> *Principal Investigator: Beatrice A. Golomb*

>>

>> *Link to the UCSD Statin Study Website*

>>

>> *Funded: Harry Frank Guggenheim Foundation*

>>

>> *Project Title: Low Serum Cholesterol and Violent Behavior*

>>

>> *Amount: \$30,000 per annum*

>>

>> *Dates: 1–1–96 to 1–1–98*

>>

>> *Principal Investigator: Beatrice A. Golomb*

>>

>>

>>

>> -----

>>

>> *TOPICS OF INTEREST*

>>

>> ** Medical Reasoning (an abiding and unifying current interest, that serves as the foundation for my interest in much of that below)*

>>

>> ** Illness in Persian Gulf War veterans (ongoing work for RAND funded by the Department of Defense, book available on RAND's website; first to synthesize information on Nerve Agent Pretreatment drug, "PB", with neurobiological literature; concluded that a role cannot be excluded.*

>>

>> ** Lipids: work in UCSD Dept of Medicine. Currently am PI of a ~5 million dollar NIH study to evaluate noncardiovascular impact of lipid reduction using statins; Work for RAND has included development of quality-of-care indicators for hyperlipidemia.*

>>

>> ** Violence (work on link between lipids and violence; single-author article in Annals of Internal Medicine synthesizing clinical work with neurobiology; prompted a five-column article in the New York Times on this work in March 1998). This work continues, partially at USC in collaboration with Dr. Sarnoff Mednick; and with collaborators in Scandinavia; I was PI of Guggenheim grant (at USC) examining relation of lipids to violence.*

>>

>> ** Risk Benefit Assessment, with focus on restoring the risk to risk-benefit. Fundamentally paradigm-shifting insights have been presented at several talks, but not yet submitted for publication. I have shown that randomized trials are performed in a way that is inherently biased to demonstrate benefit and fail to show harm, if it*

>> *is present. Moreover, a much heralded "new paradigm" in which*
>> *cardiovascular disease risk is evaluated and used to determine*
>> *aggressiveness of preventive treatments (a paradigm utilized by*
>> *national guidelines for cholesterol and hypertension, among others)*
>> *provides a one-sided look: It notes that potential benefit varies from*
>> *individual to individual, and should be assessed (based on predictors*
>> *of cardiovascular disease) to guide aggressiveness of preventive*
>> *treatments. It implicitly (and improperly) assumes that treatment*
>> *risks, if any, are fixed and need not be formally assessed. To the*
>> *contrary, potential for harm also varies from individual to*
>> *individual, and can also often be estimated by examining risk factors*
>> *for adverse outcomes. Failure to consider treatment risks on par with*
>> *treatment benefits means some individuals will receive treatment*
>> *though potential harm exceeds benefit; while others may be denied*
>> *treatment though potential benefit exceeds harm.*
>>
>> ** Cardiovascular risk: work at UCSD in collaboration with Dr. Michael*
>> *Criqui, pertaining to lipids (and the preeminence of the total*
>> *cholesterol/HDL-cholesterol ratio as a predictor of cardiovascular*
>> *risk); alcohol and cardiovascular disease risk; peripheral artery*
>> *disease; and subclinical cardiovascular disease. Some of this work has*
>> *been cited in Cecil's Textbook of Internal Medicine, a preeminent*
>> *medical text. Work for RAND in this area has included development of*
>> *quality of care indicators for stroke, for men and for the frail*
>> *elderly (two distinct RAND projects).*
>>
>> ** Placebos: Methodologically vital observation published as a letter*
>> *to the Editor in Nature that the basis of "evidence-based" medicine,*
>> *the placebo controlled trial, rests on the assumption that placebos*
>> *are inert; but in fact there are no requirements about what goes into*
>> *them, their composition remains unpublished, and the drug companies*
>> *manufacturing the agent being tested typically determine the*
>> *composition. Moreover, there is no evidence that any agent is inert to*
>> *the degree required by recent very large clinical trials designed to*
>> *tap small effects; therefore, a positive, negative, or same direction*
>> *effect of a placebo can generate the spurious appearance of a*
>> *negative, positive, or null effect of the agent under scrutiny.*
>> *Moreover there are demonstrable cases of such problems arising in the*
>> *older literature, when placebo composition was actually sometimes*
>> *stated. Advised change in policy, at the minimum requiring placebo*
>> *composition to be stated in medical journals, and offered other*
>> *suggestions to mitigate the problem. Wrote a follow-up invited*
>> *Editorial in Chemistry and Biology.*
>>
>> ** Sex Recognition: Constructed the first neural network to identify*
>> *sex of a person from raw photographic images of their face; the*
>> *recognition task is difficult for humans when face is stripped of most*
>> *hair, makeup, and jewelry cues, and the "SexNet" actually did slightly*
>> *better than tested humans. This was the perhaps the first*
>> *demonstration that NNs could solve problems that, say, decision trees*
>> *could not solve – because we had no a priori concept of what features*

>> *were relevant, and permitted the network to figure this out. (We then
>> examined the hidden units to learn from the network.)*
>>
>> ** Facial Expressions (did the initial work on use of neural networks
>> in evaluating facial expressions; wrote the scientific part of NIH
>> grant proposal that funded continued work at the Salk in this area.)*
>>
>> ** Hiccups: Read the world's literature on this, my chosen topic for
>> the minor proposition exam for my PhD; can mount a good defense that I
>> am the world's expert in this topic. Wrote a draft of an opus on this
>> topic and have given medical lectures.*
>>
>> ** Foreign Body Munchausen's (identified the hitherto unrecognized link
>> between serial foreign body ingestion and the fabled Munchausen's
>> syndrome; manuscript in preparation.)*
>>
>> ** Visual perception and illusions (topic of PhD thesis): "Discovered"/
>> constructed two new visual illusions.*
>>
>> *Back to Top*
>>
>>
>>

>> -----

>>
>> **PUBLICATIONS**

>>
>> **RESEARCH PAPERS**

>>
>> *Golomb BA, Stattin H, Mednick SA 2000. "Low cholesterol and violent
>> crime", J Psychiatric Res, in press.*
>>
>> *Golomb BA, Pyne JM, Wright B, Lohr JM, Bozzette SA 2000. "Primary care
>> for patients with severe mental illness: What role can psychiatrists
>> play?". Psychiatric Services, in press.*
>>
>> *Golomb BA, Criqui MH, Detrano RC, Wong ND, Bundens WP, Mattrey RF,
>> Denenberg JO 1999. "Noninvasive testing to detect subclinical
>> cardiovascular disease. What is its role?", Preventive Cardiology
>> 2(4):42-50 (Fall supplement).*
>>
>> *Golomb BA 1998. "Low cholesterol and violence: Is there a
>> connection?", Annals of Internal Medicine, 128:478-487.*
>>
>> *Criqui MH, Golomb BA 1998. "Epidemiologic aspects of lipid
>> abnormalities", American Journal of Medicine, 105 (1A): 48S-57S.*
>>
>> *Stewart-Bartlett M., Viola PA, Sejnowski TJ, Golomb BA, Larsen J,
>> Hager JC and Ekman P 1996 "Classifying facial action", Advances in
>> Neural Information Processing Systems 8: 823-829.*

>>
>> *Gray MS, Lawrence DT, Golomb BA and Sejnowski TJ 1995 "A perceptron
>> reveals the face of sex", Neural Computation, 7(6)1160-64.*
>>
>> *Golomb B, Lawrence DT, and Sejnowski TJ 1991, "SexNet: A neural
>> network that recognizes sex from human faces", Advances in Neural
>> Information Processing Systems 3, 572-577.*
>>
>> *Golomb B, Andersen RA, Nakayama K, MacLeod DIA, Wong A 1985, "Visual
>> thresholds for shearing motion in monkey and man", Vision Research 25,
>> 813-820.*
>>
>>
>>

>> -----

>>
>> **EDITORIALS AND INVITED COMMENTARY**
>>
>> *Criqui MH and Golomb BA 1999 "Should patients with diabetes drink to
>> their health?", Journal of the American Medical Association 282
>> (3):279-80.*
>>
>> *Golomb B and Criqui M 1999 "Antihypertensives: Much Ado About Lipids",
>> Archives of Internal Medicine, 159: 535-537.*
>>
>> *Golomb B 1998 "Dietary Fats and Heart Disease: Dogma Challenged",
>> Journal of Clinical Epidemiology 51(6): 461-464.*
>>
>> *Golomb BA 1995 "Are Placebos Bearing False Witness?", Chemistry and
>> Industry 21: 900.*
>>
>>
>>

>> -----

>>
>> **BOOKS**
>>
>> *Golomb BA 1999. "A Review of the Scientific Literature as it Pertains
>> to Gulf War Illnesses, Vol 2: Pyridostigmine Bromide". Washington, DC,
>> RAND (Has undergone external scientific peer review) Pp 1-385.*
>>
>>
>>

>> ----- **TECHNICAL REPORTS AND RAND REPORTS**

>> *Golomb B 1999. Assessing the Care of Vulnerable Elders. Potential
>> Quality Indicators and Literature Review: Stroke. 113 pages.*
>>
>> *Perry W, Johnson D, Cecchine G, Golomb B, Hilborn L, Hearn A, Anthony*

- >> *R 1999. Issues and Insights from the Army Medical Technology Workshop,*
- >> *1999. Prepared for the US Army Training and Doctrine Command and the*
- >> *US Army Medical Department. PM-946-A, July 1999.*
- >>
- >> *Hilborne L and Golomb BA 2000. "A Review of the Scientific Literature*
- >> *as it Pertains to Gulf War Illnesses, Vol 1: Infectious Diseases".*
- >> *Washington, DC, RAND – in press.*
- >>
- >> *Golomb BA "Cerebrovascular disease", in Asch S, Kerr E, Geschwind S,*
- >> *Clark K, Hamilton E, Heslin K, McGlynn EA (Eds.) Quality of Care for*
- >> *Cardiopulmonary Conditions: A Review of the Literature and Quality*
- >> *Indicators. RAND (Draft publication, Aug 1997): 42-62.*
- >>
- >> *Golomb BA "Chronic obstructive pulmonary disease", in Asch S, Kerr E,*
- >> *Geschwind S, Clark K, Hamilton E, Heslin K, McGlynn EA (Eds.) Quality*
- >> *of Care for Cardiopulmonary Conditions: A Review of the Literature and*
- >> *Quality Indicators. RAND (Draft publication, Aug 1997): 63-87.*
- >>
- >> *Golomb BA "Hyperlipidemia", in Asch S, Kerr E, Geschwind S, Clark K,*
- >> *Hamilton E, Heslin K, McGlynn EA (Eds.) Quality of Care for*
- >> *Cardiopulmonary Conditions: A Review of the Literature and Quality*
- >> *Indicators. RAND (Draft publication, Aug 1997): 169-185.*
- >>
- >> *Golomb BA "Peptic ulcer disease", in Asch S, Kerr E, Geschwind S,*
- >> *Clark K, Hamilton E, Heslin K, McGlynn EA (Eds.) Quality of Care for*
- >> *General Medical Conditions A Review of the Literature and Quality*
- >> *Indicators. RAND (Draft publication, Sep 1997): 242-268.*
- >>
- >> *Hays RD, Vickrey BG, Golomb B "Health related quality of life measures*
- >> *in studies of stroke", RAND, report to Pfizer, Inc., July 1997.*
- >>
- >> *Sherbourne CD, Golomb BA, Bystritsky A, Inkeles M, Marshall G "Summary*
- >> *of Health-related Quality of Life Measures for Use in Anxiety*
- >> *Disorders", RAND, report to Pfizer, Inc., July 1997.*
- >>
- >> *Gray MS, Lawrence DT, Golomb BA and Sejnowski TJ, (1993) "A perceptron*
- >> *reveals the face of sex", Institute for Neural Computation Technical*
- >> *Report Series, INC-9303.*
- >>
- >>
- >>
-
- >> -----
- >>
- >> **BOOK CHAPTERS**
- >>
- >> *Golomb B. Health and Medical Factors: Cholesterol. In Encyclopedia of*
- >> *Violence in the United States , Charles Scribner's Sons, 1999.*
- >>
- >> *Golomb B and Sejnowski TJ, "Sex recognition from faces using neural*
- >> *networks". In: A. F. Murray (Ed.), Applications of Neural Networks,*

>> *Kluwer Academic Publishers 1995.*

>>

>>

>>

>> -----

>>

>> *THESIS*

>>

>> *Golomb B 1988, "Visual Motion Processing: Some Special Properties",*

>> *PhD Thesis, Department of Biology, U. C. San Diego.*

>>

>>

>>

>> -----

>>

>> *LETTERS TO THE EDITOR*

>>

>> *Golomb BA 1998 "Cholesterol and violence: Is there a connection".*

>> *Annals of Internal Medicine 129(8): 669–670.*

>>

>> *Golomb BA 1996 "Low serum cholesterol and serotonin metabolism --*

>> *other studies have been done in humans and monkeys. BMJ*

>> *312(7041):1299.*

>>

>> *Golomb BA 1996 "Using placebos," Nature 379: 765.*

>>

>> *Golomb BA 1995 "Low cholesterol and violence," Arch Intern Med 155:*

>> *2485.*

>>

>> *Golomb BA 1995, "Paradox of placebo effect," Nature 375: 530.*

>>

>> *Golomb B 1990, "Hiccup for hiccups," Nature 345: 774.*

>>

>> *Golomb B 1989, "Taking a byte out of time," JAMA 262: 3132.*

>>

>>

>>

>> -----

>>

>> *BOOK REVIEWS*

>>

>> *Golomb BA 1997 "Catalyst -- For Change in Book Reviews", Chemistry and*

>> *Biology 4: 651–652.*

>>

>> *Golomb BA 1996 "Genius talk or moron babble? The complementarity*

>> *principle", Chemistry and Biology 3: 813–814.*

>>

>> *Golomb BA 1995 "Author's Imagination" (Review of Nature's Imagination:*

>> *The Frontiers of Scientific Vision) Chemistry and Biology 2(10):*
>> 651–2.
>>
>> *Back to Top*
>>
>>
>>

>> -----

>>
>> *LECTURES, PRESENTATIONS & ABSTRACTS*
>>

>>
>>
>>
>> *LECTURES & PRESENTATIONS*
>>

>> *"Medical Care: Restoring the Risk to Risk–Benefit Analysis".*
>> *University of Chicago Health Sciences group; Chicago, IL, Feb 8, 2000.*
>>
>> *"Gulf War Illness", VASDHS Medicine Faculty Development series, June*
>> *11, 1999.*
>>

>> *"Aspirin for Primary Prevention of Coronary Artery Disease" Debate vs*
>> *Dr. Felicio. Dept of Medicine quarterly conference series, "Why Do We*
>> *Do It?", VA San Diego Healthcare System, Mar 26, 1999.*
>>

>>
>>
>> *"Cholesterol and Violence: Where do we go from here?" Health Services*
>> *Research and Development Seminar Series, San Diego VAMC/UC San Diego,*
>> *Feb 11 1999.*
>>

>> *"Cholesterol and Violence", Colloquium, Social Science Research*
>> *Institute, USC, Los Angeles, CA, Nov 19, 1998.*
>>

>> *"Cholesterol and Violence", Grand Rounds, Dept of Psychiatry, UC San*
>> *Diego, La Jolla, CA, Nov 12, 1998.*
>>

>> *Invited speaker and panelist: "How might interdisciplinary models of*
>> *research guide us to a better understanding of violence?" USC*
>> *Interdisciplinary Perspectives for Understanding and Preventing*
>> *Violence, co–sponsored by the Violence Prevention Coalition of Greater*
>> *Los Angeles, Long Beach, CA, Apr 17, 1998.*
>>

>> *"Cholesterol and Violence", Dept of Psychology Colloquium, UCSD, San*
>> *Diego, Apr 16, 1998.*
>>

>> *"Measurement and Management of Hyperlipidemia for the Primary*
>> *Prevention of Coronary Heart Disease", with Dr. Michael H. Criqui.*
>> *Primary Care Grand Rounds, UCSD Dept of Family and Preventive*
>> *Medicine, San Diego, Apr 15, 1998*
>>

- >> *"The Cholesterol Controversy", VA San Diego Healthcare System*
- >> *quarterly "Why Do We Do It?" seminar, La Jolla, CA, Mar. 29, 1997.*
- >>
- >> *"Cholesterol and Violence: The Serotonin Connection", Mc Donnell Pew*
- >> *Research Center, Warner Springs Ranch, CA, Mar. 15, 1997.*
- >>
- >> *"Cholesterol and Violence", USC Dept. of Preventive Medicine, Los*
- >> *Angeles, CA, Feb 21, 1997.*
- >>
- >> *"The Cholesterol Controversy", San Diego VAMC, La Jolla, CA, Jan 10,*
- >> *1997.*
- >>
- >> *"Hyperlipidemia Panel Discussion" Discussants: Alistair Fyfe, MD, PhD;*
- >> *B. Golomb, MD, PhD; David Heber, MD. UCLA Department of Medicine Grand*
- >> *Rounds, Los Angeles, CA, Aug 14, 1996.*
- >>
- >> *"Cholesterol and Violence: Is There a Connection?" RAND/UCLA Child and*
- >> *Adolescent Health Policy Seminar, RAND, Santa Monica, CA, July 9,*
- >> *1996.*
- >>
- >> *"Cholesterol and Violence: The Serotonin Connection", Telluride Summer*
- >> *Research Center Public Lecture, Telluride, CO, July 5, 1996.*
- >>
- >> *"Cholesterol and Violence: New Evidence," UCLA Health Services*
- >> *Research Seminar Series, Los Angeles, CA, June 21, 1996.*
- >>
- >> *"Cholesterol Reduction: When is it Indicated?" Cardiology Grand*
- >> *Rounds, Cedars Sinai Medical Center, Los Angeles, CA, June 18, 1996.*
- >>
- >> *"Cholesterol, Serotonin, and Violence: Is there a Connection?," The*
- >> *Helmholtz Society, UC Irvine, Irvine, CA, June 11, 1996.*
- >>
- >> *"Cholesterol Reduction in Primary Prevention: When is it Indicated?"*
- >> *Cedars Sinai Medical Center, Health Services Research Group, Los*
- >> *Angeles CA, Mar 6, 1996.*
- >>
- >> *"Cholesterol Reduction: When and Who?" St. Johns Medical Center, Santa*
- >> *Monica, CA, Nov 2, 1995.*
- >>
- >> *"The Cholesterol Controversy": The Alzheimer Disease Research*
- >> *Consortium of Southern California, USC, Los Angeles, CA, Apr 21, 1995.*
- >>
- >> *"Cholesterol Reduction in Primary Prevention": Debate vs Dr. David*
- >> *Leaf. WLA VA Medical Center, Dept. of Medicine Grand Rounds, Mar 8,*
- >> *1995.*
- >>
- >> *"The Cholesterol Controversy," UCLA Dept. of Medicine Grand Rounds,*
- >> *Jan 11, 1995.*
- >>
- >> *"Neural Networks Distinguish Demented Subjects from Elderly Controls*
- >> *based on EEGs", Neural Information Processing Systems conference,*

>> *Neural Networks in Medicine workshop, Vail, CO, December 3, 1994.*

>>

>> *"Cholesterol Reduction in Primary Prevention: Rethinking the Evidence," UCLA Dept. of Endocrinology Grand Rounds, September 21, 1994.*

>>

>> *"Advance Directives", West Los Angeles VA Medical Center, Dept. of Medicine Conference, September 16, 1994.*

>>

>> *"The Cholesterol Myth," Grand Rounds, West Los Angeles V. A. Medical Center, Dept. of Medicine, June 8, 1994.*

>>

>> *"Death by Hiccup," Reno V. A. Medical Center, Dept. of Medicine Conference, Reno Nevada, February 1994.*

>>

>> *"Hiccups," V. A. West Los Angeles Medical Center, Dept. of Medicine Conference, January 1994.*

>>

>> *"Neural Networks that Recognize Sex and Expressions from Faces", in an international conference, Facial Expression: Brain, Perception, and Development, The Salk Institute, April 6, 1991.*

>>

>>

>>

>> -----

>>

>> **ABSTRACTS**

>>

>> *Golomb, BA "Could dysregulation of acetylcholine (from pyridostigmine bromide or other acetylcholinesterase inhibitors) contribute to illness in Persian Gulf War veterans? Conference on Federally Sponsored Gulf War Veterans' Illnesses Research, June 23–25, 1999 (Abstract accepted; withdrawn for security reasons at request of DoD)*

>>

>> *Golomb BA and Criqui MH 1998 "Put the risk back in risk–benefit", 1998 San Diego Biostatistics & Epidemiology Research Exchange Conference. La Jolla, CA (Platform presentation 5–5–98.)*

>>

>> *Bagley S and Golomb BA 1998 "Patient interest and response to genetic testing for cancer susceptibility: A systematic review of the literature", American Federation for Medical Research, Western Regional Meeting, Feb 4–7, Carmel, CA. J Investigative Medicine 46(1):*

>>

>> *Pyne J, Golomb B, Schten E, Jaworski B, Bozzette S 1998 "Appropriate roles for psychiatrists delivering primary medical care", VA HSR&D meeting, February 1998.*

>>

>> *Golomb BA 1996 "Low cholesterol and Violent Crime" Proceedings of the Robert Wood Johnson Clinical Scholars Program 24th National Meeting, Ft. Lauderdale, FL. (Platform presentation, Nov 1996.)*

- >>
- >> *Golomb BA 1995 "Cholesterol, serotonin, and violence: Is there a connection?" Proceedings of the Robert Wood Johnson Clinical Scholars Program 23rd National Meeting, Ft. Lauderdale, FL. (Platform presentation, Nov 9, 1995.)*
- >>
- >> *Golomb B and Leuchter AF "Neural Networks Distinguish Demented Patients from Elderly Controls Based on EEG Recordings" Solomon Scholar Research Award, UCLA. (Platform presentation, June 1993.)*
- >>
- >> *Golomb B, Lawrence D, Sejnowski T, and Ekman P. "Neural Networks Evaluate Facial Muscle Actions" Solomon Scholar Research Award, UCLA, 1992. (Platform presentation, June 1992.)*
- >>
- >> *Golomb B 1990, "Cross adaptation to flow field motion", Investigative Ophthalmology and Visual Science 31 (4):522. Poster presentation, Association for Research in Vision and Ophthalmology, Sarasota, FL, April 1989.*
- >>
- >> *Golomb B 1988, "Motion Escape", Investigative Ophthalmology and Visual Science 29. Poster presentation, Association for Research in Vision and Ophthalmology, Sarasota, FL, April 1988.*
- >>
- >> *Golomb B 1986, "The Crankshaft Effect", Investigative Ophthalmology and Visual Science 27(3): 345. Poster presentation, Association for Research in Vision and Ophthalmology, Sarasota, FL, April 1986.*
- >>
- >> *Golomb B, Andersen, RA, Nakayama, K, MacLeod, DIA, Wong, A. 1984 "Thresholds for shearing motion detection in monkey and man". Investigative Ophthalmology and Visual Science 25(3):69. Poster presentation, Association for Research in Vision and Ophthalmology, Sarasota, FL, April 1984.*

>> *Back to Top*

>>
>>
>>

>> -----

>>
>> **BRIEFINGS AND EXPERT PANELS**

>>
>>
>>

>> **EXPERT PANEL PARTICIPATION**

>>
>>

>> *Panelist and speaker at event sponsored by the Violence Prevention Coalition of Greater Los Angeles, entitled "How might interdisciplinary models of research guide us to a better understanding of violence?" 11-98*

>>

>>

>> *Expert panelist for NIH (NHLBI) Review Panel on "Prevention of
>> Cardiovascular Disease in Diabetes Mellitus: Clinical Center Network
>> Proposals"*

>>

>>

>>

>> *Expert "panelist" for the Department of Defense in the Army After Next
>> AMEDD Technical Workshop (aka "War Games") in MacLean, Virginia, to
>> help determine strategies for troop health protection (6-13 to 6-18,
>> 1999)*

>>

>>

>>

>> *Expert panelist for the Center for Health Policy Research/Health Care
>> Financing Association "Normative Standards Project", pertaining to
>> normative standards for home health care 6-99 (requested;
>> participation aborted due to date conflict with panel #3)*

>>

>>

>>

>> -----

>>

>> *PRESENTATIONS BEFORE EXPERT PANELS*

>>

>> *11-97: Briefings to Cardiopulmonary Expert Panel (panel of nationally
>> recognized experts): separate briefings on Stroke; Hyperlipidemia; and
>> COPD, toward development of quality of care indicators for these
>> conditions*

>>

>> *10-97: Briefings to General Medicine Expert Panel (panel of nationally
>> recognized experts): briefing on Dyspepsia/Peptic Ulcer Disease,
>> toward development of quality of care indicators for these conditions*

>>

>>

>>

>> -----

>>

>> *BRIEFINGS TO GOVERNMENT AGENCIES*

>>

>> *"Pyridostigmine Bromide: A Review of the Scientific Literature as it
>> Pertain to Gulf War Illnesses ", Testimony to Congress: House Veterans
>> Affairs Committee, Health Subcommittee and Benefits Subcommittee:
>> 11-19-99*

>>

>> *Briefings to members of Senate subcommittees (Foreign Affairs and
>> Veterans Affairs): 10-19-99*

>>

>> *"Pyridostigmine Bromide: A Review of the Scientific Literature as it
>> Pertain to Gulf War Illnesses ", Briefing to representatives of
>> multiple U.S. Veterans advocacy groups: 10-19-99*
>>
>> *"Pyridostigmine Bromide: A Review of the Scientific Literature as it
>> Pertain to Gulf War Illnesses ", Press Briefing from the Pentagon:
>> 10-19-99*
>>
>> *"Pyridostigmine bromide and illness in Persian Gulf War veterans"
>> Briefing to group consisting of: the Undersecretary of Health; the
>> Undersecretary of the Army; the Surgeon General of the Army; the
>> Principal Deputy for Health Affairs; representatives from the Surgeons
>> General of the Navy and Air Force; several other generals; and the
>> Directors of the Health and Defense Programs at RAND, in Washington
>> DC, on the effect of pyridostigmine bromide in illness in Gulf War
>> veterans. Feb 3, 1998, Washington DC. (The group convened for the
>> exclusive purpose of hearing my briefing.)*
>>
>> *"RAND on PB and Immunizations", Presidential Special Oversight Board
>> for Department of Defense Investigations of Gulf War Chemical and
>> Biological Incidents, Oct 28, 1998. Special Oversight Board Office,
>> Arlington VA.*
>>
>> *"RAND Center for Military Health Policy Research: Gulf War Illness"
>> (with Dr. Ross Anthony). Briefing to Major General James B. Peake,
>> Commanding General/Commandant/ Installation Commander, US Army Medical
>> Department Center and School. Oct 22, 1998. RAND Arroyo Center, Army
>> Research Division, Santa Monica.*
>>
>> *"Health Effects of Service in the Gulf War". Briefing to DARPA and DSO
>> (Defense Science Office), (with Dr. Ross Anthony). Sept 8, 1998,
>> DARPA, Arlington, VA.*
>>
>> *"Health Effects of Service in the Gulf War". Briefing to Advisory
>> Board of the National Defense Research Institute, (with Dr. Ross
>> Anthony). May 5, 1998, RAND, Santa Monica.*
>>
>> *"Health Effects of Service in the Gulf War". Briefing to RAND Board of
>> Trustees (with Dr. Ross Anthony), RAND's 50th birthday. April 9, 1998,
>> Washington, DC*
>>
>> *"Pyridostigmine bromide and illness in Persian Gulf War veterans".
>> Briefing to representatives from DoD, VA, FDA, PAC, and Congress. RAND
>> Washington, Nov 4, 1997, Washington DC.*
>>
>> *"Pyridostigmine bromide". Briefing to Israeli Defense and Health
>> personnel, as part of a mission to the Middle East with Dr. Bernard
>> Rostker (Assistant Secretary of the Navy; now Undersecretary of the
>> Army) and others from the DoD, Nov 1 1997, Tel Aviv, Israel;
>> participated in other briefings in the Middle East (Kuwait, Saudi
>> Arabia, and Egypt) during a ~2 week trip.*

>>
>> *Back to Top*
>>
>>
>>

>> -----

>>
>> *MEDIA RECOGNITION AND ATTENTION*

>>
>> *MEDIA RECOGNITION OF WORK*

>>
>> *National media recognition related to:*

>>
>> *1.. Neural networks (CNN, popular book, 1990).*
>> *2.. Cholesterol and violence (KNBC TV 11-97; NY Times 5 column*
>> *article,*
>> *CNN, NBC, ABC, CBS, LA Times, Reuters/AP, other 3-98).*
>> *3.. Alcohol and diabetes (Fox News, Science News, 7-99); and*
>> *4.. Pyridostigmine bromide and illness in Gulf War veterans (front*
>> *page*
>> *article on NY Times and LA Times; multiple other newspapers; NPR,*
>> *other radio stations, national TV news on ABC and CBS (lead story),*
>> *NBC; CNN, CSPAN; websites including policy.com, lead news story on*
>> *Yahoo, comedycentral.com; science journals including New Scientist)*
>> *International:*

>>
>> *1.. For cholesterol and violence work, British newspapers;*
>> *2.. For pyridostigmine bromide work: BBC radio interview, TV news*
>> *throughout Western Europe, Eastern Europe, Britain, Australia,*
>> *newspapers and news magazines throughout same distribution.*

>> -----

>>
>> *MEDIA ATTENTION*

>>
>> *1.. Neural Networks/ facial expression:*

>>
>> *a.. CNN News 1990*

>>
>> *2.. Neural Networks/ gender recognition ("SexNet"):*
>> *q.. Daily Show, Comedy Central, Oct 1999 (TV show and website)*
>> *r.. Policy.com, Oct 1999*
>> *s.. International coverage: TV, newspapers, and news magazines*
>> *throughout Europe (e.g. England, Germany, Hungary)*

>>
>>
>> *7.. Pyridostigmine bromide (PB) and illness in Gulf War veterans:*

>> *Congressional Testimony*

>> a.. *CSPAN live and replay, Nov 16 and Nov 20, 1999*

>>

>>

>> 8.. *Commentary on others' Gulf War work:*

>> a.. *NBC News (local, channel 7/39, 11-30-99)*

>> b.. *NPR radio, 12-7-99)*

>>

>> *"Don Kirkman" <donkirk@covad.net> wrote in message*

>> *news:773jt0do1k3qm61iff8q9elvcohlca7jj@4ax.com...*

>>> *It seems to me I heard somewhere that Sharon Hope wrote in article*

>>> *<Rp3Cd.742898\$mD.174164@attbi_s02>:*

>>>

>>>> *The 15% is a measurement of fact.*

>>>>

>>>> *The issue is what is being measured. What is being measured is not*

>>>> *the general population of cardiac patients nor the general population*

>>>> *of statin users. What is being measured is Dr. Golomb's caseload,*

>>>> *which is almost certainly not typical of most statin users because,*

>>>> *first, she is in a university setting with patients who to some*

>>>> *extent are self-selected and in general would be expected to be more*

>>>> *serious cases and, second, who may have sought her out because of her*

>>>> *interest in statin effects. The bulk of statin users are unlikely to*

>>>> *be seeing a doctor at a university or VA clinic.*

>>>> --

>>>> *Don*

>>>> *"I do not feel obliged to believe that the same God who has endowed*

>>>> *us with senses, reason, and intellect has intended us to forgo their*

>>>> *use. --Galileo Galilei*

>>

>>

>>

>